Additional file 11 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Additional file 11 of Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis

Additional file 11: Figure S11. Sensitivity analyses of (a) PFS and (b) OS in patients with EGFR-TKIs treatments in all-lines setting. Abbreviations: PFS, progression-free survival; OS, overall survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Qin, Kang, Hou, Helei, Liang, Yu, Zhang, Xiaochun
Format: Video
Sprache:eng
Schlagworte:
Biological Sciences not elsewhere classified
Biotechnology
Cancer
FOS: Biological sciences
FOS: Health sciences
Genetics
Infectious Diseases
Medicine
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Additional file 11: Figure S11. Sensitivity analyses of (a) PFS and (b) OS in patients with EGFR-TKIs treatments in all-lines setting. Abbreviations: PFS, progression-free survival; OS, overall survival; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
DOI:10.6084/m9.figshare.12144480